Lolophar SRL
Lolophar reported total assets of 248,113 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jan 2026).
The score of Lolophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +63 % Total assets +42 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Lolophar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 44,318 € | ||||
| Equity | 223,957 € | ||||
| Cash | 154,458 € | ||||
| EBITDA | 74,583 € | ||||
| Total assets | 248,113 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 30 Jan 2026
- Year ended 30 Jun 2024filed on 29 Jan 2025
- Year ended 30 Jun 2023filed on 02 Jan 2024
- Year ended 30 Jun 2022filed on 27 Jan 2023
- Year ended 30 Jun 2021filed on 05 Jan 2022
Lolophar's financial analysis
- Solvency90.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Lolophar
Lolophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0829.477.187
- VAT number
- BE0829477187
- Peppol
- Registered · 0208:0829477187 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Sep 2010
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 30 Jan 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Lolophar (SRL) has been based in Ghent since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 44,318 € and equity of 223,957 €; its revenue is not published. Its solvency stands at 90.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Lolophar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Johan Coppens Retail sale of pharmaceutical products Ghent · balance sheet 248,919 €
- Pharma Daive Retail sale of pharmaceutical products Péruwelz · balance sheet 247,671 €
- Apoteek Bellekens Retail sale of pharmaceutical products Antwerp · balance sheet 247,504 €
- Pharmacie Michèle BRULIAU Retail sale of pharmaceutical products Bastogne · balance sheet 249,253 €
- Schaffen Pharma Retail sale of pharmaceutical products Diest · balance sheet 246,323 €
- Fasylpharma Retail sale of pharmaceutical products Aiseau-Presles · balance sheet 250,318 €
- Sapos Retail sale of pharmaceutical products Aalst · balance sheet 241,792 €
- Odepharma Retail sale of pharmaceutical products Koksijde · balance sheet 255,295 €
Frequently asked questions about Lolophar
What is the revenue of Lolophar?
Lolophar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Lolophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0829477187 for Lolophar, if the company is VAT-registered. Its company number (CBE) is 0829.477.187.
Where is the registered office of Lolophar?
According to the CBE register, the registered office of Lolophar is in 9000 Ghent.
What is the equity of Lolophar?
At the close of the 2025 financial year, the equity of Lolophar amounts to 223,957 €, a solvency of 90.3% of total assets.
Who manages Lolophar?
The register lists 1 active mandates at Lolophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Lolophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →